MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	Complete if Known		
ANFORMATION DISCLOSURE	Application Number	10/677,227	
STATEMENT BY APPLICANT	Filing Date	10/03/2003	
MAR 1 4 2006 STATEMENT BY APPLICANT	First Named Inventor	Hiroaki ITO	
Date Submitted.	Group Art Unit	1646	
(use as many sheets as necessary)	Examiner Name	Prema MERTZ	
1 of 1	Attorney Docket Number	053466-0365	•

U.S. PATENT DOCUMENTS							
Examiner Initials*		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
PM	B1	5,888,510		Kishimoto et al.	03/30/1999		
		•					
							
			 				
			 				

Examiner	Cite	F	oreign Patent D	Ocument	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	No.1	Office ³	³ Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	MM-DD-YYYY		T ⁶
PM	B2	JP	8-208514		Chugai Pharmaceutical Co. Ltd.; Kishimoto CHUZO	08/13/1996		Abs
PM	B3	wo	96/00081	A1	Immunex Corporation	01/04/1996		1
pm	B4	wo	97/38104	A	Applied Research Systems Ars Holding N. V.	10/16/1997		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [®]					
PM	B5	IGAKU, Vol. 51, No. 10, 1996, pgs. 111-121, with Partial Translation.						
PM	B6	Jpn. J. Clin. Immun., Vol. 20, No. 2, 1997, pgs. 87-94.						

		1111		
Examiner Signature	Prema	Merk	Date Considered	12/4/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Oligi the Labernow (1995)		
number. Substitute for form 1449B/PTO	C	complete if Known
	de di di a Number	Unassigned 10/677227
INFORMATION DISCLOSURE	Application Number	10/03/2003
STATEMENT BY APPLICANT	Filing Date	Hiroaki ITO et al.
	First Named Inventor	
Date Submitted: October 3, 2003	Group Art Unit	1646
, and shorts as soccessory)	Examiner Name	Unassigned Prema Mens-
(use as many sheets as necessary)		053466-0365
Shoot 1 of 2	Attorney Docket Number	000.00

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		U.S. Patent	Document	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Where Relevant Passages or Relevant
Examiner Initials*	Cite No.1	Number	Kind Code ² (if known)		MM-DD-YYYY	Figures Appear
_,						
	 				<u> </u>	

				FC	REIGN PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	No 1 Cor 3 Number 4 Kind		Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T⁰
PM	A1	wo	96/40966	A1	Private Biologicals Corporation	12/19/1996	·	+
	A2	JP	7-324097			11/26/1996		
	A3	JP	8-311098			09/24/1996		_
	A4	JP	8-245414			090/9/1997		-
	A5	JP_	9-235276			04/16/1996		
	A6	JP	8-99996			09/03/1996		
	A7	JP	8-50829			12/19/1996		
	A8	wo	96/409966		The Board of Regents of	12/05/1996	l .	
	A9	wo	96/38481		the University of Oklahoma	12/10/1997		_
	A10	EP	0 811 384		SEIYAKU et al.	12/16/1999		
	A11	wo	99/64069		Ophidian Pharmaceuticals, Inc.	1271071000		

	<u>'</u>	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁸
pM	A12	POWRIE et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease In scid Mice	-
	A13	TAKAGI et al., "Blockage Of Inteneukin-to Receptor Adda (1908)	-
	A14		-
	A15	Monoclonal Antibody (cA2)", Gastroenterology, vol. 103.125 Transport of Ulcerative Colitis", Journal of	+
V	A16	Monoclonal Antibody (CAZ), Gastroenterology, Vol. 100 Treatment of Ulcerative Colitis", Journal of SASAJIMA et al., "Changes in Serum Cytokine Profile During Treatment of Ulcerative Colitis", Journal of Gastroenterology and Hepatology, December 1997, page A274, vol. 12, no. SUPPL., XP-001105732.	

					· · · · · · · · · · · · · · · · · · ·
1	Examiner	Ø	Ment	Date Considered	12/4/06
	Signature	runa		fermane with MPEP 609. Draw line through citation if	not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number. Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: October 3, 2003

(use as many sheets as necessary) Sheet

Complete if Known					
Application Number	Unassigned 10/6-772-27				
Filing Date	10/03/2003				
First Named Inventor	Hiroaki ITO et al.				
Group Art Unit	1646				
Examiner Name	Unassigned Prema Ment				
Attorney Docket Number	053466-0365				

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
Examiner tnitials*		U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of Cited Document	Where Relevant Passages or Relevant
	Cite No.	Number	Kind Code ² (if known)	Cited Document	· MM-DD-YYYY	Figures Appear

					FC	REIGN PATENT DOCUMEN	TS Date of Publication of	Pages, Columns, Lines,	Τ
Examiner Initials*	Cite No.1		<u>in Patent D</u> Number⁴	ocument Kind Co (if know	de	Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
									 -
		 							

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
		OTHER PRIOR ART - NON PATENT ETTERSTORE 500					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					
PM	A17	FUNAKOSHI et al., "Spectrum of Cytokine Gene Expression in Intestinal Mucosal Lesions of Cronn's Disease and Ulcerativre Colitis", Digestion, January 1998, pages 73-78, vol. 59, no. 1, Basel, China,					
, 1		XP-001064174. TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis: Relation to Intestinal Permeability", Digestion, TATEISHI et al., "Role of Cytokines in Experimental Colitis in Experimental C					
	A18	1997, pages 271-281, Vol. 56, No. 5, Baser, Olivia, Page Paget Disease", Journal of Pediatric	\dagger				
	A19	SEIDMAN et al., "Nutritional Issues in Pediatro Illiaminatory (Castroenterology and Nutrition, 1991, pages 424-438, vol. 12, no. 4, Raven Press, Ltd., New York,	_				
	A20	XP-001105792.					
-	AZU	382-389. KMIEC, "Cytokines in Inflammatory Bowel Disease," Arch. Immunol. Ther. Exp. (Warsz), Vol. 46, No. 3,	+				
	A21	KMIEC, "Cytokines in Inflammatory Bowel Disease, Authority With Inflammatory Bowel Disease-Future	+				
	A22	1998, pp. 143-155. HOGEZAND et al., "Selective Immunomodulation in Patients With Inflammatory Bowel Disease-Future Therapy or Reality?" Neth. J. Med. February 1996, Vol. 48, No. 2, pp. 64-67.					

				7	
Examiner	Bearing	Ment	Date Considered	12/4/	06
Signature	inna	3	Develop through citation if	not in conformance and	i not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.31 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if ⁵Kind of document under WIPO Standard ST. 18 if possible is the document under WIPO Standard ST. 18 if possible is the document under WIPO Standard ST. 18 if possible is the document under WIPO Standard ST. 18 if possible is the document under WIPO Standard ST. 18 if possible is the document under WIPO Sta

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.